news
Progesterone could help treat breast cancer
9 July 2015 | By Victoria White
Around half of all breast cancer patients could one day benefit from having the cheap and widely-available hormone progesterone added to their treatment...
List view / Grid view
Oncology
news
Lilly and SCRI team up to develop investigational oncology therapy
17 June 2015 | By
Lilly and SCRI have entered a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor...
news
First patient enrolled in Phase II trial of ImmunoPulse IL-12
17 June 2015 | By Victoria White
OncoSec has enrolled the first patient into a Phase II clinical trial of ImmunoPulse IL-12 in patients with squamous cell carcinoma of the head and neck...
news
ORYX’s oncolytic parvovirus H1 successfully completes Phase I/IIa trial to treat glioblastoma multiforme
12 June 2015 | By Victoria White
ORYX's Phase I/IIa trial assessing oncolytic parvovirus H1 as a treatment for patients with glioblastoma multiforme has been successfully completed...
news
First patient in Singapore treated with BTG’s TheraSphere radioembolization therapy
11 June 2015 | By Victoria White
The first patient in Singapore has been treated with TheraSphere radioembolization therapy- a treatment for primary liver cancer and metastatic bowel cancer...
news
Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics
10 June 2015 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated...
news
Exalenz Bioscience launches clinical study for breath-based detection of primary liver cancer
4 June 2015 | By Victoria White
Exalenz Bioscience has initiated a clinical study designed to investigate its BreathID test to non-invasively detect primary liver cancer...
news
AVEO receives European regulatory guidance regarding potential marketing authorisation application for tivozanib
4 June 2015 | By Victoria White
AVEO has received confirmation of support from two CHMP members following pre-submission meetings to discuss the potential submission of a MAA for tivozanib...
news
Trabectedin shown to improve disease control in patients with advanced soft tissue sarcoma
3 June 2015 | By Victoria White
Janssen Research & Development has announced data from a Phase 3 study of trabectedin (YONDELIS) in patients with two common types of soft tissue sarcoma...
news
Idelalisib in combination with ofatumumab improves progression-free survival in previously-treated patients with chronic lymphocytic leukaemia
1 June 2015 | By Victoria White
Results from a study of idelalisib in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukaemia have been announced...
news
World first as viral immunotherapy T-VEC shows patient benefit in Phase III trial
26 May 2015 | By Victoria White
A genetically engineered herpes virus, T-VEC, can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action...
news
First patient dosed in Phase 2 study of tipifarnib in advanced cancers with HRAS mutations
18 May 2015 | By Victoria White
The first patient has been dosed in the Phase 2 clinical trial of tipifarnib in patients with locally advanced tumours that carry HRAS mutations...
news
Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO 2015
11 May 2015 | By Victoria White
Roche has announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2015).
news
Positive results from Phase 2 study of APD403 in chemotherapy-induced nausea & vomiting
6 May 2015 | By
Acacia Pharma has announced positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV)...
news
First patient dosed in Phase 1 trial of CM-24, a novel immune checkpoint inhibitor for cancer immunotherapy
20 April 2015 | By Victoria White
The first patient has been dosed in a Phase 1 clinical trial of CM-24, a first-in-class immunomodulatory mAb for the treatment of various types of cancers...
